We are creating a new wave of medicines
powered by the human microbiome.
Our Ecobiotic® drugs are a novel approach
to the treatment of disease.
Our C. difficile product candidate received FDA
Breakthrough Therapy designation.
Seres Therapeutics has built a proprietary discovery and design platform that enables us to understand the dysbiosis associated with specific diseases.More
We are developing a novel class of biological drugs designed to treat disease by restoring the function of a dysbiotic microbiome.More
We have multiple active clinical studies to evaluate our microbiome therapy clinical candidates.More